Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11390038 | 0.88 | HPGD (0.64) | HSP90AA1CYP3A4HPGDTSHRALDH1A1 | |
| SCHEMBL15219985 | 0.85 | CYP3A4 (0.56) | HSP90AA1CYP3A4TSHRALDH1A1CYP1A2 | |
| SCHEMBL8349898 | 0.82 | TRPM8 (0.62) | HSP90AA1CYP3A4HPGDTSHRALDH1A1 | |
| SCHEMBL19806127 | 0.80 | HSP90AA1 (0.53) | HSP90AA1CYP3A4HPGDTSHRALDH1A1 | |
| SCHEMBL11693746 | 0.80 | HRH2 (0.55) | HSP90AA1CYP3A4CYP1A2MEN1KMT2A | |
| SCHEMBL16312618 | 0.80 | HRH2 (0.55) | HSP90AA1CYP3A4CYP1A2MAPTHRH2 | |
| SCHEMBL95064 | 0.79 | HPGD (0.65) | HSP90AA1CYP3A4HPGDTSHRALDH1A1 | |
| SCHEMBL6413796 | 0.79 | HPGD (0.52) | HSP90AA1CYP3A4HPGDTSHRALDH1A1 | |
| SCHEMBL6413801 | 0.79 | HPGD (0.52) | HSP90AA1CYP3A4HPGDTSHRALDH1A1 | |
| SCHEMBL10107755 | 0.78 | HSP90AA1 (0.66) | HSP90AA1CYP3A4HPGDTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | ICOS, CD14, MAVS | HSP90AA1 1324/4885CYP3A4 2903/4885HPGD 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.